Xenon Pharmaceuticals Inc. — Director's Dealing 2021

Jun 1, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Xenon Pharmaceuticals Inc. (XENE)
CIK: 0001582313
Period of Report: 2021-05-27

Reporting Person: HOLLER FRANK A (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-05-27	Common Shares	M	3086	$3.76	Acquired	125127	Direct
2021-05-27	Common Shares	F	507	$18.88	Disposed	124620	Direct
2021-05-27	Common Shares	M	36008	$3.76	Acquired	160628	Direct
2021-05-27	Common Shares	F	5911	$18.88	Disposed	154717	Direct
2021-05-27	Common Shares	S	2579	$18.69	Disposed	152138	Direct
2021-05-27	Common Shares	S	8485	$18.68	Disposed	143653	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-05-27	Stock Option (Right to Buy)	$3.76	M	3086	Disposed	2021-05-28	Common Shares (3086)	Direct
2021-05-27	Stock Option (Right to Buy)	$3.76	M	36008	Disposed	2021-05-28	Common Shares (36008)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Shares	1184	Indirect

Footnotes

F1: The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise.

F2: Represents the closing price of the Company's common shares on May 26, 2021, which was converted to a Canadian dollar amount for purposes of net settlement calculations.

F3: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $18.51 to $18.92, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein

F4: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $18.54 to $18.92, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein

F5: The shares subject to the option fully vested on December 31, 2013. The date the options became fully vested was incorrectly reflected on the Reporting Person's Form 3.

F6: Expiration date differs from originally reported date due to an automatic extension provided by the option plan as a result of the original expiration date falling during a Company blackout period and a lock-up agreement period.